Department of Preventive Medicine, Yonsei University College of Medicine, Yonsei-Ro 50-1, Seodaemun-Gu, Seoul, 03722, South Korea.
Department of Psychiatry and Institute of Behavioural Science in Medicine, Yonsei University College of Medicine, Seoul, Korea.
BMC Med. 2024 Oct 23;22(1):489. doi: 10.1186/s12916-024-03704-5.
Previous research has shown that the use of renin-angiotensin system (RAS) blockers is linked to a lower prevalence of posttraumatic stress disorder (PTSD), but longitudinal studies are scarce. We aimed to estimate the association between the use of RAS blockers and the risk of PTSD among individuals taking antihypertensive medications.
This longitudinal study included participants aged 40-69 from the UK Biobank. Exposure data were obtained from the initial assessment (2006-10), while outcome data were obtained from the online mental health questionnaire administered 6-11 years later (2016-17). We included participants who were under antihypertensive treatment and did not have a prior diagnosis of PTSD before the initial assessment. Use of RAS blockers was defined as self-reported regular use, at the initial assessment, of angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB). Among participants who experienced adverse life experiences, cases of probable PTSD were defined with the six-item PTSD Checklist-Civilian version score ≥ 14. Logistic regression with inverse probability of treatment weighting was used to estimate the odds ratios (ORs) and 95% confidence interval (CI) for the association between RAS blocker use and the risk of probable PTSD.
Of the 15,954 participants (mean age = 59.9 years; 42.6% women) under antihypertensive treatment with no prior history of PTSD at the initial assessment, 64.5% were taking RAS blockers. After a mean follow-up of 7.5 years, 1,249 (7.8%) were newly identified with probable PTSD. RAS blocker users had a lower risk of probable PTSD than RAS blocker non-users (OR = 0.84 [95% CI: 0.75-0.94]), whereas the use of other antihypertensive medications showed no such association (users vs. non-users; calcium channel blockers, OR = 0.99 [95% CI: 0.88-1.11]; beta-blockers, 1.20 [1.08-1.34]; and thiazide-related diuretics, 1.15 [1.03-1.29]). The association between probable PTSD risk and the use of ACEi vs. ARB showed no significant difference (p = 0.96).
Among individuals under antihypertensive treatment, the use of RAS blockers was associated with a decreased risk of probable PTSD. This added benefit of RAS blockers should be considered in the selection of antihypertensive medications.
先前的研究表明,使用肾素-血管紧张素系统(RAS)阻滞剂与创伤后应激障碍(PTSD)的患病率较低有关,但纵向研究较为缺乏。我们旨在评估在服用抗高血压药物的人群中,使用 RAS 阻滞剂与 PTSD 风险之间的关联。
这项纵向研究纳入了来自英国生物库的年龄在 40-69 岁的参与者。暴露数据来自于初始评估(2006-10 年),而结局数据来自于 6-11 年后进行的在线心理健康问卷调查(2016-17 年)。我们纳入了正在接受抗高血压治疗且在初始评估前没有 PTSD 既往诊断的参与者。RAS 阻滞剂的使用定义为在初始评估时报告的定期使用,包括血管紧张素转换酶抑制剂(ACEi)或血管紧张素受体阻滞剂(ARB)。在经历过不良生活经历的参与者中,使用六分量表 PTSD 清单-平民版评分≥14 分来定义可能的 PTSD 病例。使用逆概率治疗加权的逻辑回归来估计 RAS 阻滞剂使用与可能的 PTSD 风险之间的关联的比值比(OR)和 95%置信区间(CI)。
在 15954 名(平均年龄 59.9 岁;42.6%为女性)正在接受抗高血压治疗且在初始评估时没有 PTSD 既往史的参与者中,有 64.5%的人服用 RAS 阻滞剂。在平均 7.5 年的随访后,有 1249 名(7.8%)新确诊为可能的 PTSD。与未使用 RAS 阻滞剂的患者相比,使用 RAS 阻滞剂的患者发生可能的 PTSD 的风险较低(OR=0.84[95%CI:0.75-0.94]),而其他抗高血压药物的使用则没有这种关联(使用者与非使用者相比;钙通道阻滞剂,OR=0.99[95%CI:0.88-1.11];β受体阻滞剂,1.20[1.08-1.34];噻嗪类相关利尿剂,1.15[1.03-1.29])。ACEi 与 ARB 使用者发生可能的 PTSD 风险之间的关联没有显著差异(p=0.96)。
在接受抗高血压治疗的人群中,使用 RAS 阻滞剂与可能的 PTSD 风险降低有关。在选择抗高血压药物时,应考虑 RAS 阻滞剂的这种附加益处。